Dr. Roger Flugel, PhD, is a healthcare and pharmaceutical executive with nearly 30 years of experience across executive management, corporate development, drug development, medical marketing, regulatory affairs, and international business operations.
He has served as CEO, board director, venture capital investor, and strategic advisor to companies in the areas of biotechnology, pharmaceuticals, supplements, wellness and longevity. He has extensive hands-on experience advancing drug programs from discovery through Phase 1, 2, and 3 clinical trials world-wide, securing financing, negotiating business partnerships, and overseeing regulatory medical affairs.
Dr. Flugel’s current technical interests are in the areas of innovating and commercializing new strategies and treatments for chronic disease, wellness, anti-aging, and medical esthetics, to improve lifespan, healthspan, and overall quality of life. This includes doing research to support new product development and distribution of innovative supplements, peptide therapies, and exploring new alternate off-label use of “older” established FDA-approved medicines such as rapamycin, metformin, and tadalafil, for their potential to safely increase human longevity.
